Results 1 to 10 of about 125 (92)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study

PLoS ONE, 2022
ObjectiveThe aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy ...
Irina Strazhesko, Ekaterina Bryushkova, Dmitry Chudakov   +2 more
exaly   +5 more sources

Effectiveness of netakimab in psoriasis and psoriatic arthritis with concomitant metabolic syndrome

Vestnik Dermatologii I Venerologii
Psoriasis and psoriatic arthritis are characterized by a high prevalence, a chronic progressive course, the frequent presence of severe forms, comorbidities, and a significant decrease in patients’ quality of life, which justifies high demands on the ...
L. A. Novikova, E. V. Dontsova, A. A. Bakhmetyev, L. N. Borzunova, A. Yu. Kuranosov, N. A. Voronkova   +5 more
exaly   +4 more sources

Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice [PDF]

Vestnik Dermatologii i Venerologii, 2023
Rationale. Data from randomized clinical trials (RCTs) may differ from the results of the efficacy and safety of medicines in the conditions of daily work. Purpose.
Andrey L. Bakulev, Olga A. Pritulo, Zhanna S. Kuntsevich, Alkes A. Khotko, Anastasiya A. Yunovidova, Pavel V. Gorognichev, Oleg R. Ziganshin, Natalya S. Rudneva, Evgeniya V. Bildyuk, Tatiana V. Repina, Valentina Y. Dudko, Mariya D. Maksimova   +11 more
doaj   +2 more sources

Real-world experience with netakimab in the treatment of spondyloarthritis

Терапевтический архив, 2023
Aim. To study the real-world efficacy and safety of netakimab in the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Materials and methods.
Alexey D. Meshkov, Natalya M. Vorobyeva, Valentina S. Ostapenko, Valentina S. Pykhtina, Viktoriya I. Ruzanova, Olesia A. Perlova, Irina S. Kordyukova, Anton V. Naumov, Natalia O. Khovasova, Olga N. Tkacheva   +9 more
doaj   +3 more sources

Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19) [PDF]

European Cytokine Network, 2021
Cytokine release syndrome is a serious complication of the new coronavirus infection (COVID-19). The aim of the study was to assess effectiveness and safety of the IL-17 antagonist nekatimab for its treatment. The retrospective study included COVID-19 patients with C-reactive protein levels >60 mg/L. Patients received either netakimab (group NET), IL-6
Roman Maslennikov
exaly   +3 more sources

Netakimab in the therapy of psoriatic onychodystrophy

Медицинский совет, 2022
Psoriatic onychodystrophy affects up to 50% of patients with psoriasis and up to 80% of patients with psoriatic arthritis, with an estimated lifetime risk of nail plate changes in this patient population of up to 90%. Nail psoriasis is characterised by a
O. V. Zhukova, S. I. Artemyeva, A. Al-Hawatmi, E. A. Pechatnikova   +3 more
doaj   +2 more sources

Fab Fragment of V_HH-Based Antibody Netakimab: Crystal Structure and Modeling Interaction with Cytokine IL-17A [PDF]

Crystals, 2019
Interleukin 17A (IL-17A) is a proinflammatory cytokine produced by Th17 cells. Antibody BCD-085 (netakimab) against human IL-17A is one of the new inhibitors of this cytokine.
Olga Kostareva, Ilya Kolyadenko, Andrey Ulitin, Victoria Ekimova, Stanislav Evdokimov, Maria Garber, Svetlana Tishchenko, Azat Gabdulkhakov   +7 more
doaj   +3 more sources

Successful use of Netakimab in the treatment of psoriasis accompanied by the psoriatic onychodystrophy

Медицинский совет, 2020
Psoriasis is a chronic immune-mediated disease that is accompanied by a significant number of comorbid pathologies. Damage to the nail plates (psoriatic onychodystrophy) is widespread among patients with psoriasis and is associated with significant ...
N. N. Potekaev, O. V. Zhukova, S. I. Artemyeva   +2 more
doaj   +4 more sources

Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study

Научно-практическая ревматология, 2021
Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis.
T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. A. Sevastyanova, A. V. Eremeeva   +9 more
doaj   +3 more sources

Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study

Doklady Biochemistry and Biophysics
Background. Netakimab has shown high efficacy in controlled clinical trials in the treatment of patients with ankylosing spondylitis (AS). This article presents results of an observational study of netakimab using in routine clinical practice.Methods ...
Vadim Mazurov, Shandor Erdes, I F Umnova   +2 more
exaly   +3 more sources